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Background: The purpose of the study was to measure the retinal venous pressure (RVP) in the eyes of primary
open-angle glaucoma (POAG) patients and healthy subjects with and without a Flammer-Syndrome (FS).
Methods: RVP was measured in the following four groups of patients and age- and sex-matched healthy controls:
(a) 15 patients with a POAG and a FS (POAG/FS+); (b) 15 patients with a POAG but without a FS (POAG/FS-); (c) 14
healthy subjects with a FS (healthy/FS+) and (d) 16 healthy subjects without a FS (healthy/FS-). RVP was measured
in all participants bilaterally by means of contact lens ophthalmodynamometry. Ophthalmodynamometry is done
by applying increasing pressure on the eye via a contact lens. The minimum force required to induce a venous
pulsation is called ophthalmodynamometric force (ODF). The RVP is defined and calculated as the sum of ODF and
intraocular pressure (IOP) [RVP = ODF + IOP].
Results: The participants with a FS (whether patients with POAG or healthy subjects), had a significantly higher RVP
compared to subjects without a FS (p = 0.0103). Patients with a POAG and FS (POAG/FS+) had a significantly higher
RVP compared to patients without a FS (POAG/FS−) (p = 0.0301). There was a notable trend for a higher RVP in the
healthy/FS + group compared to the healthy/FS − group, which did not reach statistical significance (p = 0.0898).
Conclusions: RVP is higher in subjects with a FS, particularly in glaucoma patients. The causal relationship needs to
be further evaluated.Background
Disturbances of ocular blood flow are involved in many
ophthalmic diseases and are therefore of utmost clinical
relevance [1-5]. There are various causes for blood flow
disturbances, such as diseased blood vessels [6] or mech-
anical compression of the vessel wall [7]. However, some
organs are not well perfused, despite anatomically
healthy blood vessels, when the regulation of blood flow
is not adapted to the needs of the tissue [8]. Such a vas-
cular dysregulation implies either inappropriate vasocon-
strictions (vasospasms) or an insufficient vasodilation
(more or less than is required) [9]. Dysregulation can be
secondary in nature, as in multiple sclerosis [10], wherein
the high level of Endothelin-1 reduces ocular blood flow
OBF. Dysregulation can also be primary in nature (pri-
mary vascular dysregulation or PVD) [9], meaning that it
can occur without any underlying disease and caused by* Correspondence: Maneli.Mozaffarieh@usb.ch
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uli, such as cold temperatures or mechanical or emotional
stress. The combination of PVD with a cluster of add-
itional vascular and non-vascular signs and symptoms is
what is known today as the Flammer-Syndrome [11,12].
The eye is one of the best-perfused organs in the body.
One factor influencing this process is the ocular perfu-
sion pressure (OPP) [13-17]. OPP is the difference
between systemic blood pressure and the RVP. In the
eye, arterial pressure is assumed to be 2/3 of the brachial
arterial pressure. The RVP is assumed equal to the IOP.
The latter assumption is not always true in glaucoma
patients [18-21].
As summarized in the literature reviews, glaucoma pa-
tients often concomitantly suffer from a FS [22,23]. One
of the clinical observations that we made in patients
with a FS was that they often had dilated retinal veins,
which is why we hypothesized that RVP may be higher
in FS than in non-FS subjects. We therefore set out to
measure RVP in glaucoma patients and healthy subjects
with and without a FS.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographic and baseline characteristics of the
four groups of participants
POAG/FS+ POAG/FS− Healthy/FS+ Healthy/FS−
N 15 15 14 16
Gender (F/M) 8/7 7/8 7/7 10/6
Age Mean (SD) 67.0 (8.7) 62.8 (8.7) 60.4 (13.2) 56.5 (10.6)
IOP Mean (SD) 10.6 (1.5) 13.33 (2.55) 11.71 (1.33) 13.12 (3.3)
Patients with POAG and FS: POAG/FS +.
Patients with POAG but without FS: POAG/FS −.
Healthy subjects with FS: Healthy/FS + .
Healthy subjects without FS: Healthy/FS −.
Table 2 List of local and systemic treatment regimens of
the POAG patients
Local & systemic therapy POAG/FS+ POAG/FS−
Local Therapy N 15 15
Timolol & Dorzolamide 1 0
Timolol & Dorzolamide & Tafluprost 4 5




No local Therapy 4 3
Systemic Therapy N 15 15
Ginkgo biloba (120 mg daily) 1 2
Ginkgo biloba (120 mg daily) &
Magnesium (10 mmol daily)
6 3
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Patients with POAG were recruited from the University
Eye Clinic, Basel, between January 2011 and December
2012. Healthy volunteers, age- and sex-matched to the
POAG patients, were recruited in our outpatient depart-
ment. The control subjects did not have any relevant eye
disease and attended our outpatient department for vari-
ous reasons, including prescriptions for eyeglasses, dry
eye symptoms and regular ophthalmic check-up exami-
nations. Ethical approval was obtained from the local med-
ical ethics committee of Basel City (‘Ethik Kommission
Beider Basel’ or EKBB) to measure RVP in healthy controls
who gave oral consent to take part in the study (Reference
Number 272/11). No ethical approval was required to
measure RVP in glaucoma patients as RVP measurements
are always taken in all glaucoma patients at the Depart-
ment of Ophthalmology of the University of Basel. For in-
clusion, the patients with POAG met the following criteria:
(1) glaucomatous visual fields or glaucomatous optic nerve
cupping and (2) the absence of alternative causes of optic
neuropathy.
FS was defined as being present if it was detected in
the patient history and confirmed by the dynamic retinal
vessel analyser (DVA). Cases in which the patient history
and DVA results were contradictory were excluded from
the study.
Evaluation of patient history for FS
FS is defined as present (FS+) in the patient history if the
subjects answer three of the following six questions with
“Yes”, and it is defined as absent (FS-) if the subjects an-
swer less than three questions with “Yes”: 1) Do you suffer
from cold hands or feet even in summer [24]?; 2) Do you
have trouble falling asleep, especially when you are cold
[25]?; 3) Are you seldom thirsty, and do you have to re-
mind yourself to drink enough [26]?; 4) Do you suffer from
migraine attacks [27]?; 5) Do you have low blood pressure
[28]?; 6) Do you identify smells better than others [29]?
Evaluation of DVA results for FS
The results of DVA were considered positive for FS
(pathological) if the reaction of the arteries in both eyes
was reduced in response to flickering light.
Cases in which the patient history and DVA results
were contradictory were excluded from the study. The
following groups of subjects were compared: (1) POAG
patients with a FS (POAG/FS+); (2) POAG patients
without a FS (POAG/FS−); (3) healthy controls with a
FS (healthy/FS+) and (4) healthy controls without a FS
(healthy/FS−). Table 1 presents the demographic data of
the different groups of subjects. Table 2 lists the local
and systemic treatment regimens of the POAG patients.
For all patients and controls, RVP was measured in
both eyes by ophthalmodynamometry (Meditron GmbH,Völklingen, Germany). This device consists of a conven-
tional Goldmann contact lens fitted with a pressure sen-
sor at its outer margin where the Goldmann contact
lens is usually held during an ophthalmoscopic examin-
ation. The device is connected to an LCD screen.
Ophthalmodynamometry is conducted by applying
increasing pressure to the eye via the contact lens. This
applied pressure can be read as an IOP increase on the
attached LCD screen based on a calibration curve. The
IOP increase that is required to induce a venous pulsa-
tion is called the ophthalmodynamometric force (ODF).
If a spontaneous venous pulsation is present, ODF is
said to be 0, if not present, increasing pressure is
applied. The RVP is defined and calculated as the sum
of the ODF and IOP [RVP =ODF + IOP]. Measurements
by the ophthalmodynamometer are reproducible [30].
Statistical analysis
RVP was analysed with a linear fixed effects model. The
participant group (POAG/FS+, POAG/FS−, healthy/FS +
and healthy/FS−) was taken as ‘fixed effect’, and partici-
pants (patients and healthy controls) were taken as
‘random effects’ to account for repeated measures.
Gender and age were included as covariates to account
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to meet the assumption of normally distributed errors.
Three a priori defined group comparisons were made:
FS + vs FS−, POAG/FS + vs POAG/FS − and Healthy/FS +
vs Healthy/FS −.Results
The visual acuities in the FS + group ranged from 20/100
to 20/20 and the mean deviation (MD) in the visual field
ranged from −3.2 to −10.9. In the FS- group the visual
acuities ranged from 20/100 to 20/20 and MD in the
visual field ranged from −2.9 to −12.1.
Five of the patients in the POAG/FS + group and two
patients in the POAG/FS- group had low blood pressure,
but neither of these patients was treated with salt tablets
or fludrocortisone at the time when RVP was measured.
Participants with a FS (whether patients with a POAG
or healthy subjects), had a significantly higher RVP com-
pared to participants without a FS (P = 0.0103). Patients
with a POAG and FS had a statistically significant higher
RVP compared to patients with a POAG but without FS
(p = 0.0301, Figure 1).
There was a notable trend for a higher RVP in the
healthy/FS + group compared to the healthy/FS − group,
which did not reach statistical significance (p = 0.0898).Figure 1 Intraocular pressure (IOP) and retinal venous pressure (RVP)
deviation of base line measurements are shown; for RVP mean ±1 staRVP of healthy subjects was on average 23% higher
compared to healthy subjects without FS (Figure 1).
No significant differences in RVP were found between
the two eyes of all participants (Table 2).Discussion
The term vascular dysregulation in the context of
glaucoma was first introduced by Flammer [9]. Later, a
distinction was made between primary and secondary
vascular dysregulation [31]. A secondary vascular dys-
regulation occurs in the context of another disease, such
as rheumatoid arthritis [32] whereas a primary vascular
dysregulation [2], described an inborn disposition to
respond differently to stimuli. Today, the combination of
PVD with a cluster of additional vascular and non-
vascular signs and symptoms is called the Flammer-
Syndrome (FS) [11,12]. The FS can occur in otherwise
healthy subjects. Since we made the clinical observation
that glaucoma patients with a FS often had dilated
retinal veins, we hypothesized that the RVP in the subset
of glaucoma patients with a FS may be higher than in
those glaucoma patients without a FS.
Glaucoma patients have a higher RVP than controls
[18-21,33]. Our values of RVP in the glaucoma group with-
out FS (POAG/FS−) were in line with those of Jonas et al.in the four groups of participants: for IOP mean ±1 standard
ndard error are shown.
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retinal vein in their glaucoma group to be 26.1 (SD 26.4)
relative units [19]. Our results suggest that glaucoma
patients who suffer from a FS have a significantly higher
RVP than non-FS glaucoma patients. The vascular systems
of people with a FS respond differently (e.g., reacting with
vasoconstrictions to various stimuli such as cold or stress)
[34,35]. Despite the anatomically normal appearance of
their vessels, those people with a FS have stiffer retinal
vessels, as pulse waves in their retinal vessels propagate
faster compared to those of subjects without a FS [36].
The spatial irregularity of the vessels of people with a
FS is increased [37], whereas neurovascular coupling is
decreased [38], and autoregulation of ocular blood flow
is disturbed [35].
A reduced and unstable OPP has been reported to be
risk factor for glaucoma progression [13,15,39-41];
therefore, a better estimate of OPP obtained by consider-
ing RVP may reveal an even stronger relationship. At
present, the cause of this increased RVP is not known.
Theoretically, it could be due to structural changes in
the optic nerve head or to a local dysregulation at the
outflow level of the retinal vein, as already postulated for
the mechanism of a retinal vein occlusion [42]. Such
dysregulation is most likely a consequence of the local
increase of vasoactive molecules, such as Endothelin-1,
which are diffused from the circulating blood or are
produced in the neural tissue of the retina [43]. Endothelin-
1 values are higher in glaucoma patients, particularly
normal-tension glaucoma patients who commonly suffer
from a FS, compared to healthy controls [44-46].
This study has certain limitations. Central corneal
thickness was not measured as it is still a debate as to
whether it is meaningful to correct IOP by corneal thick-
ness. Caffeine consumption was also not assessed in this
study since the consumption of caffeine does not seem
to impact values of IOP or ocular perfusion pressure
(OPP) for those at risk for POAG [47]. The patients in
the FS + and FS- groups were also not fully matched
with regards to the extent of glaucomatous damage,
length or disease or local and systemic treatment.
Conclusion
In summary, FS appears to be associated with an increased
RVP particularly in glaucoma patients. The causal relation-
ship needs to be further evaluated.
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